Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/EIF4G1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/EIF4G1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/EIF4G1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/EIF4G1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/EIF4G1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/EIF4G1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/EIF4G1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/EIF4G1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:007099732 | Oral cavity | NEOLP | neuron death | 60/2005 | 361/18723 | 3.70e-04 | 3.50e-03 | 60 |
GO:00364903 | Oral cavity | NEOLP | regulation of translation in response to endoplasmic reticulum stress | 6/2005 | 11/18723 | 4.29e-04 | 3.91e-03 | 6 |
GO:006096432 | Oral cavity | NEOLP | regulation of gene silencing by miRNA | 14/2005 | 49/18723 | 4.50e-04 | 4.04e-03 | 14 |
GO:009006814 | Oral cavity | NEOLP | positive regulation of cell cycle process | 42/2005 | 236/18723 | 6.66e-04 | 5.55e-03 | 42 |
GO:190199221 | Oral cavity | NEOLP | positive regulation of mitotic cell cycle phase transition | 21/2005 | 93/18723 | 6.98e-04 | 5.78e-03 | 21 |
GO:004477231 | Oral cavity | NEOLP | mitotic cell cycle phase transition | 67/2005 | 424/18723 | 7.30e-04 | 5.98e-03 | 67 |
GO:004592722 | Oral cavity | NEOLP | positive regulation of growth | 45/2005 | 259/18723 | 7.42e-04 | 6.05e-03 | 45 |
GO:00331382 | Oral cavity | NEOLP | positive regulation of peptidyl-serine phosphorylation | 23/2005 | 108/18723 | 9.48e-04 | 7.33e-03 | 23 |
GO:190198921 | Oral cavity | NEOLP | positive regulation of cell cycle phase transition | 24/2005 | 115/18723 | 1.00e-03 | 7.68e-03 | 24 |
GO:190121431 | Oral cavity | NEOLP | regulation of neuron death | 52/2005 | 319/18723 | 1.37e-03 | 9.77e-03 | 52 |
GO:003030721 | Oral cavity | NEOLP | positive regulation of cell growth | 31/2005 | 166/18723 | 1.45e-03 | 1.03e-02 | 31 |
GO:004484331 | Oral cavity | NEOLP | cell cycle G1/S phase transition | 41/2005 | 241/18723 | 1.87e-03 | 1.28e-02 | 41 |
GO:000734631 | Oral cavity | NEOLP | regulation of mitotic cell cycle | 69/2005 | 457/18723 | 2.07e-03 | 1.38e-02 | 69 |
GO:190121531 | Oral cavity | NEOLP | negative regulation of neuron death | 36/2005 | 208/18723 | 2.54e-03 | 1.60e-02 | 36 |
GO:003313521 | Oral cavity | NEOLP | regulation of peptidyl-serine phosphorylation | 27/2005 | 144/18723 | 2.67e-03 | 1.66e-02 | 27 |
GO:200004531 | Oral cavity | NEOLP | regulation of G1/S transition of mitotic cell cycle | 25/2005 | 142/18723 | 8.58e-03 | 4.15e-02 | 25 |
GO:000218118 | Prostate | BPH | cytoplasmic translation | 115/3107 | 148/18723 | 1.08e-60 | 6.68e-57 | 115 |
GO:000641718 | Prostate | BPH | regulation of translation | 157/3107 | 468/18723 | 9.09e-20 | 5.63e-17 | 157 |
GO:000641316 | Prostate | BPH | translational initiation | 59/3107 | 118/18723 | 4.78e-17 | 1.14e-14 | 59 |
GO:003497618 | Prostate | BPH | response to endoplasmic reticulum stress | 95/3107 | 256/18723 | 1.54e-15 | 2.52e-13 | 95 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
EIF4G1 | SNV | Missense_Mutation | novel | c.4172N>A | p.Cys1391Tyr | p.C1391Y | Q04637 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A7-A0CG-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
EIF4G1 | SNV | Missense_Mutation | | c.184C>T | p.Arg62Trp | p.R62W | Q04637 | protein_coding | deleterious(0) | possibly_damaging(0.609) | TCGA-A7-A13E-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | bevacizumab | PD |
EIF4G1 | SNV | Missense_Mutation | | c.2188N>A | p.Glu730Lys | p.E730K | Q04637 | protein_coding | deleterious(0.01) | possibly_damaging(0.905) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
EIF4G1 | SNV | Missense_Mutation | | c.2701N>T | p.Arg901Cys | p.R901C | Q04637 | protein_coding | deleterious(0.01) | benign(0.344) | TCGA-BH-A0B3-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
EIF4G1 | SNV | Missense_Mutation | novel | c.364N>T | p.Val122Phe | p.V122F | Q04637 | protein_coding | deleterious(0.04) | possibly_damaging(0.862) | TCGA-BH-A0HL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
EIF4G1 | SNV | Missense_Mutation | rs571849011 | c.197C>T | p.Pro66Leu | p.P66L | Q04637 | protein_coding | deleterious(0) | benign(0.098) | TCGA-BH-A18U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
EIF4G1 | SNV | Missense_Mutation | | c.1457N>T | p.Gly486Val | p.G486V | Q04637 | protein_coding | tolerated(0.31) | probably_damaging(0.942) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
EIF4G1 | SNV | Missense_Mutation | rs73053766 | c.3791A>G | p.Asn1264Ser | p.N1264S | Q04637 | protein_coding | deleterious(0.05) | benign(0.076) | TCGA-LD-A74U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | taxotere | SD |
EIF4G1 | insertion | Frame_Shift_Ins | novel | c.3123_3124insGTTAA | p.Pro1042ValfsTer59 | p.P1042Vfs*59 | Q04637 | protein_coding | | | TCGA-A8-A093-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
EIF4G1 | insertion | Nonsense_Mutation | novel | c.3124_3125insAGAGGCAATAATGCATGA | p.Pro1042delinsGlnArgGlnTerCysMetThr | p.P1042delinsQRQ*CMT | Q04637 | protein_coding | | | TCGA-A8-A093-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |